Appili Therapeutics Inc faces a significant setback as its stock tumbles sharply.
Appili Therapeutics Inc (APLI.TO) is experiencing a steep decline in its stock price, dropping by 33.33% in today’s trading session. This downturn raises concerns among investors about the company's recent performance and strategic direction.
Investor takeaway: Investors should be cautious with Appili Therapeutics, particularly in light of recent contract terminations and the stock's drastic decline.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
-33.33%
Beta
-0.21
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
185.7%
Annualized
90-Day Vol
217.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.02 |
| 60 trading days | C$0.01 | C$0.00 – C$0.02 |
| 90 trading days | C$0.01 | C$0.00 – C$0.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Appili's stock plummets by 33.33% today
With a market cap of just CA$1.32 million, the company is under significant pressure to regain investor confidence.
Bull case
Despite today’s plunge, Appili has made progress in securing funding and promoting its product LIKMEZ® in the U.S. market, which could help the company bounce back.
Bear case
The termination notice from the NIAID regarding the VXV-01 program contract raises major concerns, indicating operational challenges that could hinder future growth.
Recent Developments
Appili Therapeutics recently received a termination notice from the NIAID regarding the VXV-01 program, alarming investors. This news, along with the company's ongoing efforts to secure funding, has contributed to today’s stock decline.
Market Reaction
The sharp drop in Appili's stock price reflects growing worries about its operational viability and future prospects. Investors are closely watching the company's next steps following this significant setback.
Looking Ahead
While the current situation looks grim, Appili’s recent achievements in securing funding and showcasing its products could provide a glimmer of hope. However, the company needs to tackle its operational challenges to regain investor trust and stabilize its stock.
Advertisement
